BNTX - BioNTech Genmab expand pact to develop cancer immunotherapies

• BioNTech ( NASDAQ: BNTX ) and Genmab ( GMAB ) are expanding their collaboration to develop and commercialize novel immunotherapies to treat patients with cancer.
• Under the new agreement, the companies will jointly develop and commercialize, subject to regulatory approval, monospecific antibodies using Genmab's HexaBody technology platform for various cancer indications.
• The first monospecific antibody candidate GEN1053/BNT313, is expected to enter clinical trials by the end of 2022.
• The companies said they will equally share the development costs and potential future profit from GEN1053/BNT313.
• The companies currently have two jointly developed investigational medicines: GEN1046/BNT311 is being evaluated in two phase 1/2 trials to treat advanced solid tumors, and in a phase 2 study in patients with non-small cell lung cancer. Meanwhile, GEN1042/BNT312 is being evaluated to treat metastatic or locally advanced solid tumors in a phase 1/2 study.
• BNTX +0.40% to $181.16, GMAB -0.39% to $35.87 premarket Aug. 5

For further details see: